cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.

Cancer Pain Drug Information

Drug Information

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Symptomatic relief of moderate to severe pain, especially associated w/ neoplastic disease, MI & surgery. ...

Indication: Peripheral & central neuropathic pain, generalised anxiety disorder (GAD) in adults. Adjunctive therapy in...

Indication: Management of chronic pain & intractable pain in patients requiring continuous opioid administration for a...

Indication: Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term ...

Indication: Adjunctive therapy in treatment of partial seizures w/ & w/o secondary generalization in adults & chil...

Indication: Moderate to severe pain.

Indication: Moderate to severe pain.

Indication: Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain.

Indication: Severe acute & chronic pain. Painful diagnostic or therapeutic measures.

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.